Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of "Hold" from Analysts

Pfizer Inc. (NYSE:PFE - Get Free Report) has been assigned a consensus recommendation of "Hold" from the fifteen analysts that are covering the company, Marketbeat reports. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $35.86.

Several brokerages have issued reports on PFE. BMO Capital Markets reaffirmed an "outperform" rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Argus downgraded Pfizer from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd. Morgan Stanley increased their price objective on Pfizer from $28.00 to $29.00 and gave the company an "equal weight" rating in a research note on Thursday, May 2nd. Cantor Fitzgerald reissued an "overweight" rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Finally, Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They set a "buy" rating and a $36.00 price target for the company.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Corient Private Wealth LLC boosted its stake in shares of Pfizer by 0.8% during the 3rd quarter. Corient Private Wealth LLC now owns 3,163,739 shares of the biopharmaceutical company's stock valued at $104,927,000 after buying an additional 25,534 shares during the last quarter. Syon Capital LLC bought a new stake in shares of Pfizer in the 3rd quarter worth about $1,011,000. NBC Securities Inc. acquired a new stake in shares of Pfizer in the 3rd quarter valued at about $2,361,000. Pinnacle Financial Partners Inc lifted its stake in Pfizer by 3.9% during the third quarter. Pinnacle Financial Partners Inc now owns 438,863 shares of the biopharmaceutical company's stock worth $14,557,000 after purchasing an additional 16,558 shares during the last quarter. Finally, Briaud Financial Planning Inc acquired a new position in Pfizer in the third quarter worth $30,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

NYSE:PFE traded down $0.90 during trading hours on Thursday, hitting $28.70. The company's stock had a trading volume of 41,998,922 shares, compared to its average volume of 42,563,102. Pfizer has a 52-week low of $25.20 and a 52-week high of $40.37. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The business's 50-day moving average is $27.24 and its two-hundred day moving average is $27.97. The company has a market capitalization of $162.63 billion, a PE ratio of -478.25, a PEG ratio of 1.11 and a beta of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm had revenue of $14.88 billion during the quarter, compared to analysts' expectations of $13.87 billion. During the same quarter last year, the business earned $1.23 earnings per share. The business's revenue for the quarter was down 19.5% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer will post 2.39 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.85%. The ex-dividend date is Thursday, May 9th. Pfizer's dividend payout ratio (DPR) is presently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.